S&P 500   3,862.12 (+0.18%)
DOW   31,093.02 (+0.43%)
QQQ   328.32 (+0.06%)
AAPL   143.76 (+0.59%)
MSFT   230.96 (+0.62%)
FB   279.82 (+0.65%)
GOOGL   1,891.97 (-0.12%)
AMZN   3,301.22 (+0.22%)
TSLA   884.87 (+0.46%)
NVDA   542.48 (-0.67%)
BABA   263.28 (+0.73%)
CGC   34.51 (+4.86%)
GE   11.93 (+8.55%)
MU   80.62 (-0.81%)
AMD   93.98 (-0.16%)
NIO   59.87 (-0.20%)
T   29.35 (+0.82%)
F   11.51 (+1.95%)
ACB   10.47 (+3.05%)
BA   207.22 (+1.90%)
DIS   172.17 (+0.16%)
NFLX   556.92 (+0.03%)
GILD   67.69 (-0.69%)
S&P 500   3,862.12 (+0.18%)
DOW   31,093.02 (+0.43%)
QQQ   328.32 (+0.06%)
AAPL   143.76 (+0.59%)
MSFT   230.96 (+0.62%)
FB   279.82 (+0.65%)
GOOGL   1,891.97 (-0.12%)
AMZN   3,301.22 (+0.22%)
TSLA   884.87 (+0.46%)
NVDA   542.48 (-0.67%)
BABA   263.28 (+0.73%)
CGC   34.51 (+4.86%)
GE   11.93 (+8.55%)
MU   80.62 (-0.81%)
AMD   93.98 (-0.16%)
NIO   59.87 (-0.20%)
T   29.35 (+0.82%)
F   11.51 (+1.95%)
ACB   10.47 (+3.05%)
BA   207.22 (+1.90%)
DIS   172.17 (+0.16%)
NFLX   556.92 (+0.03%)
GILD   67.69 (-0.69%)
S&P 500   3,862.12 (+0.18%)
DOW   31,093.02 (+0.43%)
QQQ   328.32 (+0.06%)
AAPL   143.76 (+0.59%)
MSFT   230.96 (+0.62%)
FB   279.82 (+0.65%)
GOOGL   1,891.97 (-0.12%)
AMZN   3,301.22 (+0.22%)
TSLA   884.87 (+0.46%)
NVDA   542.48 (-0.67%)
BABA   263.28 (+0.73%)
CGC   34.51 (+4.86%)
GE   11.93 (+8.55%)
MU   80.62 (-0.81%)
AMD   93.98 (-0.16%)
NIO   59.87 (-0.20%)
T   29.35 (+0.82%)
F   11.51 (+1.95%)
ACB   10.47 (+3.05%)
BA   207.22 (+1.90%)
DIS   172.17 (+0.16%)
NFLX   556.92 (+0.03%)
GILD   67.69 (-0.69%)
S&P 500   3,862.12 (+0.18%)
DOW   31,093.02 (+0.43%)
QQQ   328.32 (+0.06%)
AAPL   143.76 (+0.59%)
MSFT   230.96 (+0.62%)
FB   279.82 (+0.65%)
GOOGL   1,891.97 (-0.12%)
AMZN   3,301.22 (+0.22%)
TSLA   884.87 (+0.46%)
NVDA   542.48 (-0.67%)
BABA   263.28 (+0.73%)
CGC   34.51 (+4.86%)
GE   11.93 (+8.55%)
MU   80.62 (-0.81%)
AMD   93.98 (-0.16%)
NIO   59.87 (-0.20%)
T   29.35 (+0.82%)
F   11.51 (+1.95%)
ACB   10.47 (+3.05%)
BA   207.22 (+1.90%)
DIS   172.17 (+0.16%)
NFLX   556.92 (+0.03%)
GILD   67.69 (-0.69%)
Log in
NYSE:RMD

ResMed Stock Forecast, Price & News

$220.00
-1.68 (-0.76 %)
(As of 01/26/2021 09:35 AM ET)
Add
Compare
Today's Range
$219.95
Now: $220.00
$221.46
50-Day Range
$204.53
MA: $213.20
$220.30
52-Week Range
$108.85
Now: $220.00
$224.24
Volume150 shs
Average Volume443,769 shs
Market Capitalization$31.88 billion
P/E Ratio47.21
Dividend Yield0.72%
Beta0.28
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
ResMed logo

MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

572nd out of 1,922 stocks

Surgical & Medical Instruments Industry

58th out of 168 stocks

Analyst Opinion: 1.2Community Rank: 1.8Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP76115210
Phone858-836-5000
Employees7,770
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.96 billion
Cash Flow$6.14 per share
Book Value$17.26 per share

Profitability

Net Income$621.67 million

Miscellaneous

Market Cap$31.88 billion
Next Earnings Date1/28/2021 (Confirmed)
OptionableOptionable
$220.00
-1.68 (-0.76 %)
(As of 01/26/2021 09:35 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ResMed (NYSE:RMD) Frequently Asked Questions

How has ResMed's stock price been impacted by COVID-19?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RMD stock has increased by 44.2% and is now trading at $221.46.
View which stocks have been most impacted by COVID-19
.

Is ResMed a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ResMed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, January 28th 2021.
View our earnings forecast for ResMed
.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, January 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its earnings results on Thursday, October, 29th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.98 by $0.29. The medical equipment provider earned $751.90 million during the quarter, compared to the consensus estimate of $709.47 million. ResMed had a trailing twelve-month return on equity of 30.64% and a net margin of 22.45%. The firm's revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.93 EPS.
View ResMed's earnings history
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 29th. Stockholders of record on Thursday, November 12th will be given a dividend of $0.39 per share on Thursday, December 17th. This represents a $1.56 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date of this dividend is Tuesday, November 10th.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.56 per share and currently has a dividend yield of 0.72%. The dividend payout ratio of ResMed is 32.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 28.26% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

10 brokerages have issued twelve-month price objectives for ResMed's shares. Their forecasts range from $165.00 to $210.00. On average, they expect ResMed's stock price to reach $189.40 in the next twelve months. This suggests that the stock has a possible downside of 14.5%.
View analysts' price targets for ResMed
or view Wall Street analyst' top-rated stocks.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM, Founder & Non-Exec. Chairman (Age 78, Pay $431.8k)
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 48, Pay $2.73M)
  • Mr. Robert A. Douglas, Pres & COO (Age 60, Pay $1.99M)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 53, Pay $907.65k)
  • Dr. James R. Hollingshead Ph.D., Pres of Sleep & Respiratory Care Bus. (Age 57, Pay $1.27M)
  • Mr. Rajwant Singh Sodhi, Pres of Software as a Service Bus. (SaaS) (Age 47, Pay $1.04M)
  • Mr. Kaushik Ghoshal, Chief Technology Officer
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 61)
  • Ms. Constance C. Bienfait, Director of Investor Relations
  • Ms. Amy Wakeham, VP of Investor Relations & Corp. Communications

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Welch & Forbes LLC (0.21%), Frontier Capital Management Co. LLC (0.16%), Ardevora Asset Management LLP (0.15%), New York State Teachers Retirement System (0.13%), Capital Investment Services of America Inc. (0.10%) and Nisa Investment Advisors LLC (0.07%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Ardevora Asset Management LLP, State of Alaska Department of Revenue, Hudson Valley Investment Advisors Inc. ADV, Pacer Advisors Inc., Welch & Forbes LLC, Kestra Private Wealth Services LLC, and Campbell Capital Management Inc.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, and Robert Andrew Douglas.
View insider buying and selling activity for ResMed
or view top insider-selling stocks.

Which major investors are buying ResMed stock?

RMD stock was acquired by a variety of institutional investors in the last quarter, including Alecta Pensionsforsakring Omsesidigt, Nisa Investment Advisors LLC, Tandem Investment Advisors Inc., Janney Montgomery Scott LLC, New York State Teachers Retirement System, Crossmark Global Holdings Inc., Capital Investment Services of America Inc., and Kestra Advisory Services LLC.
View insider buying and selling activity for ResMed
or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $221.46.

How big of a company is ResMed?

ResMed has a market capitalization of $32.09 billion and generates $2.96 billion in revenue each year. The medical equipment provider earns $621.67 million in net income (profit) each year or $4.76 on an earnings per share basis. ResMed employs 7,770 workers across the globe.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.